Ascentage Acquires Global Rights to Protein Degrader Technology

Suzhou 's Ascentage Pharma acquired global rights to a MDM2 protein degrader developed at the University of Michigan . Ascentage will have exclusive rights to the Proteolysis-Targeting Chimeras (PROTACs) technology that uses the ubiquitin-proteasome system to induce degradation of targeted proteins. The lead drug candidate is currently entering IND-enabling studies. Previous MDM2 inhibitors block MDM2-p53 interactions and restore the tumor-suppressing activity of p53, but they have drawbacks, including dose-limiting toxicities. MDM2-driven tumors include leukemia. More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //